Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Women's Disease and Related Vaccine
share announcement

Women's Disease and Related Vaccine

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Papillomavirus Vaccines".

Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 7962

Special Issue Editor

Dr. Ignacio Zapardiel

E-Mail Website
Guest Editor
1. Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain
2. Obstetrics and Gynecology Department, UAM University, Madrid, Spain
3. Biomedical Research Institute – IdiPAZ, Madrid, Spain
Interests: gynecologic oncology; cervical cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleague,

In gynecology, when considering any women´s disease that could be avoided or treated with a specific related vaccine, clearly the most representative one is the cervical cancer and the HPV vaccine. During the last 10 years, we have observed a great evolution in HPV vaccines: from those based on two HPV serotypes to those based on nine HPV serotypes; from preventive vaccines to the new therapeutic vaccines which are under development; from scarce knowledge about the immunity response and its duration to new findings and crossed immunity for other serotypes not contained in the original vaccine. In parallel, knowledge about the etiopathogenesis, transmission mechanisms, and evolution of the disease have been changing in recent years as well. All these research lines and new findings make this Special Issue an opportunity to communicate promising research lines, new concepts, results of immunization on different populations (based on age, previous surgical treatments, immunosuppressed patients, etc.), and every single development related to HPV vaccines.

We hope all authors and researchers consider this opportunity to publish their work in this Vaccines journal.

Dr. Ignacio Zapardiel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • human papillomavirus
  • HPV vaccines
  • cervical cancer
  • cervical conization

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 288 KiB  
Article
Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain)
by Juan J. Hernandez-Aguado, Damián Ángel Sánchez Torres, Esther Martínez Lamela, Gema Aguión Gálvez, Eva Sanz Espinosa, Almudena Pérez Quintanilla, Daniela A. Martínez-Carrillo, Mar Ramírez Mena, Pluvio J. Coronado Martín, Ignacio Zapardiel and Jesús de la Fuente-Valero
Vaccines 2022, 10(3), 387; https://doi.org/10.3390/vaccines10030387 - 3 Mar 2022
Cited by 4 | Viewed by 2176
Abstract
A fully government-funded human papillomavirus (HPV) vaccination program started in 2007 in Spain (only 11–14-year-old girls). The first of those vaccinated cohorts, with the quadrivalent vaccine (Gardasil), turned 25 years old in 2018, the age at which cervical cancer screening begins in Spain. [...] Read more.
A fully government-funded human papillomavirus (HPV) vaccination program started in 2007 in Spain (only 11–14-year-old girls). The first of those vaccinated cohorts, with the quadrivalent vaccine (Gardasil), turned 25 years old in 2018, the age at which cervical cancer screening begins in Spain. The current study could provide the first evidence about the effectiveness of the quadrivalent vaccine against HPV in Spain and the influence of age of vaccination. The present ambispective cohort study, which was conducted on 790 women aged 25 and 26 years old, compares the rate of HPV prevalence and cytologic anomaly according to the vaccination status. The overall infection rate was 40.09% (vaccinated group) vs. 40.6% (non-vaccinated group). There was a significant reduction in the prevalence of HPV 6 (0% vs. 1.3%) and 16 (2.4% vs. 6.1%), and in the prevalence of cytological abnormalities linked to HPV16: Atypical Squamous Cells of Undetermined Significance (ASCUS) (2.04% vs. 14%), Low-grade Squamous Intraepithelial Lesions (LSIL) (2.94% vs. 18.7%) and High-grade Squamous Intraepithelial Lesion (HSIL) (0% vs. 40%), in the vaccinated group vs. the non-vaccinated group. Only one case of HPV11 and two cases of HPV18 were detected. The vaccine effectively reduces the prevalence of vaccine genotypes and cytological anomalies linked to these genotypes. Full article
(This article belongs to the Special Issue Women's Disease and Related Vaccine)
11 pages, 813 KiB  
Article
Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study
by Andrea Casajuana-Pérez, Mar Ramírez-Mena, Estefanía Ruipérez-Pacheco, Inés Gil-Prados, Javier García-Santos, Mónica Bellón-del Amo, Juan J. Hernández-Aguado, Jesus de la Fuente-Valero, Ignacio Zapardiel and Pluvio J. Coronado-Martín
Vaccines 2022, 10(2), 288; https://doi.org/10.3390/vaccines10020288 - 14 Feb 2022
Cited by 11 | Viewed by 3122
Abstract
Background: Recent data have shown that the human papillomavirus (HPV) vaccine could impact on a decrease in high-grade cervical intraepithelial lesions (HSIL) in women who have undergone surgical treatment. This study aimed to evaluate the efficacy of human papilloma virus (HPV) vaccination against [...] Read more.
Background: Recent data have shown that the human papillomavirus (HPV) vaccine could impact on a decrease in high-grade cervical intraepithelial lesions (HSIL) in women who have undergone surgical treatment. This study aimed to evaluate the efficacy of human papilloma virus (HPV) vaccination against persistent/recurrent disease in patients undergoing conization for high-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia-grade 2-3 (HSIL/CIN 2-3). Methods: From January 2009 to March 2019, 563 patients with HSIL/CIN 2-3 underwent conization. The population was divided into two groups according to vaccination status: vaccinated-group (V-Group) and non-vaccinated-group (NV-Group). Bivalent or quadrivalent vaccines were administered indiscriminately. A follow-up was scheduled every 6–12 months according to clinical guidelines. The mean follow-up was 29.6 vs. 36.5 months in the V-group and NV-group, respectively. Results: 277 (49.2%) women were vaccinated, while 286 (50.8%) were not. Overall, persistent/recurrent HSIL/CIN 2-3 was presented by 12/277 (4.3%) women in the V-Group and 28/286 (9.8%) in the NV-Group (HR: 0.43, 95% Confidence interval 0.22–0.84, p = 0.014). Vaccination was associated with a 57% reduction in HSIL persistence/recurrence after treatment. When no disease was present in the first 6-month follow-up visit, persistence/recurrence rates were very low in both groups: 1.1% in the V-Group vs. 1.5% in the NV-Group (p > 0.05). The factor associated with a high-risk of HSIL persistence/recurrence was the presentation of a positive co-test in the first control after treatment (p < 0.001). Conclusions: Our results corroborate the benefit of HPV vaccination in woman treated for HSIL/CIN 2-3, showing a reduction of persistent/recurrent HSIL/CIN 2-3. Full article
(This article belongs to the Special Issue Women's Disease and Related Vaccine)
►▼ Show Figures

Figure 1

10 pages, 248 KiB  
Article
Enhancement of Vaccination Attitude and Flu Vaccination Coverage among Pregnant Women Attending Birthing Preparation Course
by Stefania Bruno, Brigida Carducci, Gianluigi Quaranta, Viria Beccia, Andrea Di Pilla, Daniele Ignazio La Milia, Marcello Di Pumpo, Elettra Carini, Lucia Masini, Enrica Tamburrini, Antonietta Spadea, Gianfranco Damiani, Antonio Lanzone and Patrizia Laurenti
Vaccines 2021, 9(2), 183; https://doi.org/10.3390/vaccines9020183 - 21 Feb 2021
Cited by 3 | Viewed by 2085
Abstract
Most vaccinations are recommended within the 15th month of life, in order to reduce risks and to protect children from the initial stages of their lives. A vaccination training session was carried out during the birthing preparation course, aimed at increasing the attitude [...] Read more.
Most vaccinations are recommended within the 15th month of life, in order to reduce risks and to protect children from the initial stages of their lives. A vaccination training session was carried out during the birthing preparation course, aimed at increasing the attitude toward vaccination in maternal-child age. A questionnaire on vaccination awareness was administered before and after the training session and on-site flu vaccination was offered to women and their companions. The percentage of participants who consider the preparatory course a useful tool to obtain information about vaccines increases significantly from 30.34% at pre-intervention to 64.56% at post-intervention (p < 0.001). There is a significant increase in the mean number of vaccinations that the participants want their children to get. The number of participants believing that there is no relationship between vaccination and autism rose from 41.05 to 72.97% (p < 0.001). In total, 48 out of 119 (40.34%) pregnant women participating in the course and 39 companions were vaccinated for influenza. Vaccination knowledge and attitude significantly increased after a training session dedicated to vaccination as a part of the pregnant pre-birth course, whose aim can be therefore extended to the management of the health of the child, well beyond the period of pregnancy, according to the life-course approach to health. Full article
(This article belongs to the Special Issue Women's Disease and Related Vaccine)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop